Mammography Techniques — MCQs

10 questions

Which of the following stages of Breast Cancer corresponds to the following features: a breast mass of 6 x 3 cm, ipsilateral supraclavicular lymph node involvement, and distant metastasis that cannot be assessed?

Dose of radiation per study in mammography is

Gold standard investigation for breast carcinoma screening in a patient with silicone breast implants

Which of the following is the most sensitive investigation for ductal carcinoma in situ (DCIS) of the breast?

What is not an advantage of USG over mammography?

Q6Easy

For normal mammography, what is the nominal focal size of the X-ray tube used?

Q7Easy

What is the typical radiation dose delivered during mammography?

Q8Medium

Which of the following is NOT an indication of malignancy on mammography?

Q9Easy

What is the primary purpose of the BIRADS score?

Q10Medium

A patient presents with a suspicious breast lump. Ultrasonography reports the lesion as BI-RADS-4. What is your inference?

Mammography Techniques Indian Medical PG Practice Questions and MCQs

Question 1: Which of the following stages of Breast Cancer corresponds to the following features: a breast mass of 6 x 3 cm, ipsilateral supraclavicular lymph node involvement, and distant metastasis that cannot be assessed?

A. T4 N3 MX
B. T4 N1 M1
C. T4 N0 M0
D. T3 N3c MX (Correct Answer)

Explanation: ***T3 N3c MX*** - A **breast mass of 6 x 3 cm** indicates a T3 tumor (tumor size > 5 cm). - **Ipsilateral supraclavicular lymph node involvement** is classified as N3c disease. **Distant metastasis that cannot be assessed** is denoted by MX. *T4 N3 MX* - A **T4 classification** is reserved for tumors with direct extension to the chest wall or skin, or inflammatory breast cancer, which is not mentioned here. - While N3c and MX are correct for the nodal and metastatic status, the T stage is inaccurate based on the provided tumor size. *T4 N1 M1* - A **T4 classification** is incorrect as the mass size alone (6 x 3 cm) does not meet T4 criteria. - **N1** denotes involvement of 1-3 axillary lymph nodes, which is less extensive than supraclavicular involvement (N3c). **M1** indicates confirmed distant metastasis, but the question states it "cannot be assessed" (MX). *T4 N0 M0* - **T4** is incorrect, as this stage is for direct chest wall/skin involvement or inflammatory breast cancer. - **N0** signifies no regional lymph node metastasis, contradicting the presence of supraclavicular lymph node involvement. **M0** indicates no distant metastasis, whereas the question specifies it cannot be assessed (MX).

Question 2: Dose of radiation per study in mammography is

A. 3 cGy
B. 1 cGy
C. 4 cGy
D. 2 cGy (Correct Answer)

Explanation: ***2 cGy*** - The typical average glandular dose per **complete mammography study** is approximately **2 cGy (0.2 rad or 2 mGy)** for a standard two-view examination per breast. - With **modern digital mammography**, doses have been further reduced to approximately **0.4-0.8 cGy** per complete study, but **2 cGy** remains the commonly cited reference value for screening mammography in medical literature. - This dose is considered **safe for routine screening** with benefits far outweighing the minimal radiation risk. *4 cGy* - This value is **higher than the standard** radiation dose for modern mammography. - While older **film-screen mammography** systems delivered higher doses, **4 cGy** exceeds the typical exposure for a complete digital mammographic study. - This would represent an unnecessarily high dose with current technology. *3 cGy* - This value is **slightly higher** than the standard reference dose for mammography. - While closer than 4 cGy, **3 cGy** is still above the typical average glandular dose delivered in modern screening mammography. *1 cGy* - This value is **lower than the traditional reference** but actually closer to **modern digital mammography** doses (0.4-0.8 cGy per complete study). - However, in **standard medical literature and exam references**, **2 cGy** is the conventionally cited dose for mammography screening.

Question 3: Gold standard investigation for breast carcinoma screening in a patient with silicone breast implants

A. Mammography
B. CT scan
C. USG
D. MRI (Correct Answer)

Explanation: ***MRI*** - **MRI** is considered the **gold standard** for breast cancer screening in patients with silicone breast implants due to its superior ability to visualize breast tissue through the implant and detect subtle lesions. - It offers **high sensitivity** in detecting both implant rupture and early malignancies, often providing better clarity than mammography in augmented breasts where implants can obscure tissue. *Mammography* - While a standard screening tool, **mammography** can be limited in patients with silicone implants because the implants can **obscure adjacent breast tissue**, making detection of small masses challenging. - Special views (e.g., **Eklund views**) can be used, but sensitivity is still reduced compared to MRI in augmented breasts. *CT scan* - **CT scans** are not routinely used for primary breast cancer screening due to their use of **ionizing radiation** and lower sensitivity for detecting early breast lesions compared to MRI. - CT is more commonly used for **staging** advanced cancers or evaluating complex masses detected by other modalities. *USG* - **Ultrasound (USG)** is a valuable complementary tool, especially for evaluating palpable lumps or clarifying findings from mammography, but it is **operator-dependent** and has a lower overall sensitivity for general screening compared to MRI. - It is particularly useful for differentiating between **cystic and solid masses** and detecting implant ruptures but is not the gold standard for comprehensive screening in augmented breasts.

Question 4: Which of the following is the most sensitive investigation for ductal carcinoma in situ (DCIS) of the breast?

A. PET Scan
B. Ultrasound
C. Mammography (Correct Answer)
D. MRI

Explanation: ***Mammography*** - **Mammography** is the **gold standard** and **primary imaging modality** for detecting **ductal carcinoma in situ (DCIS)**, primarily because it excels at visualizing **microcalcifications**, which are the hallmark of DCIS. - Approximately **80-90% of DCIS cases** present as **microcalcifications** on mammograms, making it the most important screening and diagnostic tool. - Mammography has **high sensitivity (85-95%)** for detecting DCIS, especially calcified forms, and is widely available and cost-effective. *MRI* - While **MRI** has high sensitivity for invasive breast cancer and can detect non-calcified DCIS, it is **not the primary screening tool** for DCIS detection. - MRI is typically used for **staging known DCIS**, evaluating **extent of disease**, detecting **additional foci**, and screening **high-risk patients**. - However, MRI has lower specificity and higher false-positive rates compared to mammography, limiting its use as a primary diagnostic tool. *PET Scan* - **PET scans** are generally **not sensitive** for detecting **DCIS** because DCIS lesions typically have a **low metabolic rate** and do not avidly take up the **FDG tracer**. - PET scans are primarily used for detecting **invasive cancers** and assessing **metastatic disease**, not for non-invasive lesions like DCIS. *Ultrasound* - **Ultrasound** has **limited sensitivity** for detecting **DCIS** because DCIS often does not present as a palpable mass or a distinct sonographic abnormality. - While ultrasound can be useful for evaluating palpable masses or guiding biopsies, it frequently **misses microcalcifications** that are characteristic of DCIS. - Ultrasound is mainly used as a **complementary tool** to mammography, not as a primary diagnostic modality for DCIS.

Question 5: What is not an advantage of USG over mammography?

A. Can be used for guided biopsy
B. Superior detection of microcalcifications (Correct Answer)
C. In young females with dense breasts
D. Can be used to differentiate solid VS cystic

Explanation: ***Superior detection of microcalcifications*** - **Mammography** is the gold standard for detecting **microcalcifications**, which can be a key indicator of **ductal carcinoma in situ (DCIS)** or early invasive breast cancer. - **Ultrasound (USG)** has limited sensitivity for detecting and characterizing microcalcifications. *Can be used for guided biopsy* - **USG-guided biopsy** is a common and advantageous technique for obtaining tissue samples from suspicious lesions in the breast or other organs. - This allows for **real-time visualization** of the needle, improving accuracy and reducing complications. *Can be used to differentiate solid VS cystic* - **USG** excels at distinguishing between **solid masses and fluid-filled cysts** due to differences in sound wave reflection. - This capability is crucial in characterizing breast lesions and often eliminates the need for further invasive procedures for benign cysts. *In young females with dense breasts* - **Dense breast tissue** in young females can obscure lesions on mammography, making interpretation difficult. - **USG** is particularly valuable in this population because it is not hindered by breast density and can provide a clearer view of underlying pathology.

Question 6: For normal mammography, what is the nominal focal size of the X-ray tube used?

A. 0.2-0.25 mm
B. 0.3-0.35 mm (Correct Answer)
C. 0.4-0.45 mm
D. 0.45-0.50 mm

Explanation: In mammography, high spatial resolution is critical for detecting tiny structures like microcalcifications. The focal spot size directly influences **geometric blurring** (penumbra); a smaller focal spot results in a sharper image. ### 1. Why Option B is Correct For **routine (normal) mammography**, a nominal focal spot size of **0.3 mm** (typically ranging from 0.3 to 0.35 mm) is the standard. This size provides an optimal balance: it is small enough to ensure high detail for screening while being large enough to withstand the heat generated by the X-ray tube during standard exposures without damaging the anode. ### 2. Why Other Options are Incorrect * **Option A (0.2-0.25 mm):** This is too large for magnification but smaller than the standard for routine screening. * **Options C & D (0.4-0.5 mm):** These sizes are used in general radiography (e.g., Chest X-rays, where focal spots are often 0.6–1.2 mm). In mammography, such large spots would cause excessive geometric blurring, making it impossible to see fine architectural distortions. ### 3. High-Yield Clinical Pearls for NEET-PG * **Magnification Mammography:** When a specific area needs to be magnified, a much smaller focal spot of **0.1 mm** (range 0.1–0.15 mm) is used to compensate for the increased blurring caused by the air gap. * **Anode Material:** Usually **Molybdenum (Mo)** or Rhodium (Rh) is used to produce low-energy (soft) X-rays (25–30 kVp) for better soft-tissue contrast. * **Orientation:** The cathode is placed over the **base of the breast** (chest wall) and the anode over the **apex** (nipple) to utilize the "Heel Effect" for uniform density.

Question 7: What is the typical radiation dose delivered during mammography?

A. 0.1 Gray/study
B. 0.01 centiGray/study
C. 0.1 centiGray/study (Correct Answer)
D. 0.01 Gray/study

Explanation: ### Explanation **1. Why Option C is Correct:** The radiation dose in mammography is measured as the **Mean Glandular Dose (MGD)**, which represents the average dose to the radiosensitive glandular tissue of the breast. For a standard two-view screening mammogram (per breast), the typical dose is approximately **1 to 2 mGy (0.1 to 0.2 rad)**. Since **1 rad = 1 centiGray (cGy)**, a dose of 0.1 rad is equivalent to **0.1 cGy**. This level of radiation is considered very low and is roughly equivalent to the amount of natural background radiation a person receives over seven weeks. **2. Why Other Options are Incorrect:** * **Option A (0.1 Gray):** This is equivalent to 100 mGy. This dose is far too high for diagnostic imaging and would be closer to levels used in therapeutic radiation or causing deterministic effects. * **Option B (0.01 cGy):** This is 0.1 mGy, which is too low to produce a diagnostic quality image of dense breast tissue. * **Option D (0.01 Gray):** This is equivalent to 10 mGy (1 rad). While some complex interventional procedures might reach this level, it is significantly higher than the standard dose for a screening mammogram. **3. High-Yield Clinical Pearls for NEET-PG:** * **Target/Filter Material:** Mammography uses low-energy X-rays (typically **25–35 kVp**) to maximize soft tissue contrast. Common target/filter combinations are **Molybdenum/Molybdenum** or **Rhodium**. * **MQSA Requirement:** The Mammography Quality Standards Act (MQSA) mandates that the dose should not exceed **3 mGy (0.3 cGy)** per view with a grid. * **Screening Guidelines:** In India, the general recommendation is annual or biennial screening starting at age 40–50 years. * **Risk vs. Benefit:** The risk of radiation-induced breast cancer is negligible compared to the benefit of early detection of spontaneous breast cancer.

Question 8: Which of the following is NOT an indication of malignancy on mammography?

A. Nodular calcification (Correct Answer)
B. Speckled margin
C. Attenuated architecture
D. Irregular mass

Explanation: ### Explanation In mammography, the primary goal is to differentiate between benign and malignant features based on mass morphology, margins, and calcification patterns. **1. Why "Nodular Calcification" is the correct answer:** Nodular (or "popcorn-like") calcifications are typically large, coarse, and well-defined. These are classic features of **benign** lesions, most commonly seen in **involuting fibroadenomas**. Malignant calcifications, by contrast, are usually pleomorphic, fine-linear, or branching (casting type), representing necrotic debris within ducts (as seen in DCIS). **2. Analysis of Incorrect Options (Malignant Features):** * **Speckled (Spiculated) Margin:** This is the most specific mammographic sign of malignancy. It represents the infiltration of cancer cells into surrounding tissue and the subsequent desmoplastic reaction. * **Attenuated (Distorted) Architecture:** Architectural distortion refers to the pulling or tethering of normal breast parenchyma without a visible central mass. While it can occur in post-surgical scars, in a screening context, it is highly suspicious for invasive lobular or ductal carcinoma. * **Irregular Mass:** Malignant tumors grow haphazardly, leading to an irregular shape. Benign lesions are more likely to be round, oval, or circumscribed. **3. High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS Classification:** Used for standardized reporting. BI-RADS 4 and 5 indicate high suspicion of malignancy. * **Most specific sign of malignancy:** Spiculated margins. * **Benign Calcifications:** Popcorn (Fibroadenoma), Eggshell/Rim (Oil cysts), and Teardrop (Milk of calcium). * **Malignant Calcifications:** Fine pleomorphic or fine-linear branching (BI-RADS 5). * **Initial Investigation:** Mammography is the gold standard for screening women >40 years; Ultrasound is preferred for women <30 years or during pregnancy/lactation.

Question 9: What is the primary purpose of the BIRADS score?

A. To maintain uniformity in the reporting of imaging findings of various breast diseases (Correct Answer)
B. To prognosticate breast cancer
C. To evaluate the effect of brachial artery thrombosis
D. To establish a clinicoradiological association of breast malignancy

Explanation: **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized quality assurance tool developed by the American College of Radiology (ACR). Its primary objective is to **standardize breast imaging reporting**, reduce ambiguity in interpretations, and facilitate clear communication between radiologists and clinicians. By providing a uniform lexicon and structured assessment categories (0–6), it ensures that a specific finding carries the same clinical weight regardless of the reporting radiologist. **Analysis of Options:** * **Option A (Correct):** BI-RADS provides a universal language for describing findings (e.g., mass margins, calcification morphology) and assigns a final assessment category that dictates management. * **Option B (Incorrect):** Prognosis is determined by TNM staging, histological grade, and molecular markers (ER/PR/HER2 status), not by the initial BI-RADS score. * **Option C (Incorrect):** BI-RADS is specific to breast imaging (Mammography, USG, MRI) and has no relevance to vascular conditions like brachial artery thrombosis. * **Option D (Incorrect):** While BI-RADS guides management, its primary goal is the standardization of the *imaging report* itself, rather than establishing clinical-pathological correlations. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete; needs further imaging (e.g., spot compression or comparison with old films). * **BI-RADS 3:** Probably benign (<2% risk of malignancy); management is **short-interval follow-up** (usually 6 months). * **BI-RADS 4 & 5:** Suspicious and Highly Suggestive; both require **tissue diagnosis (biopsy)**. * **BI-RADS 6:** Known biopsy-proven malignancy; used for monitoring response to neoadjuvant chemotherapy.

Question 10: A patient presents with a suspicious breast lump. Ultrasonography reports the lesion as BI-RADS-4. What is your inference?

A. Benign lesion requiring no follow-up
B. Probably benign lesion requiring follow-up
C. Suspicious lesion requiring biopsy (Correct Answer)
D. Highly suggestive of malignancy

Explanation: **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized classification system used to communicate the risk of malignancy in breast imaging. **1. Why Option C is Correct:** **BI-RADS 4** is categorized as **"Suspicious."** Lesions in this category do not have the classic appearance of malignancy but possess features that make cancer a distinct possibility (risk of malignancy ranges from **>2% to <95%**). Therefore, the definitive management for any BI-RADS 4 lesion is a **tissue diagnosis (biopsy)**, typically via Ultrasound-guided Core Needle Biopsy. **2. Why Other Options are Incorrect:** * **Option A (BI-RADS 1 or 2):** BI-RADS 1 is a normal study; BI-RADS 2 represents definitely benign findings (e.g., simple cyst, stable fibroadenoma). Neither requires immediate intervention. * **Option B (BI-RADS 3):** These are "Probably Benign" lesions with a <2% risk of malignancy. The standard management is **short-interval follow-up** (usually at 6 months) rather than immediate biopsy. * **Option D (BI-RADS 5):** These lesions are "Highly Suggestive of Malignancy" (>95% risk). While they also require biopsy, the term "Suspicious" specifically defines Category 4. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete assessment; needs further imaging (e.g., comparison with old films or additional views). * **BI-RADS 4 Subdivisions:** 4A (Low suspicion, 2-10%), 4B (Moderate suspicion, 10-50%), and 4C (High suspicion, 50-95%). * **BI-RADS 6:** Confirmed malignancy (biopsy-proven) prior to definitive treatment like surgery or chemotherapy. * **Gold Standard:** For suspicious calcifications seen on mammography, **Stereotactic Biopsy** is the preferred method.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free